Generic Name and Formulations:
Baricitinib 2mg; tabs.
Lilly, Eli and Company
Indications for OLUMIANT:
Moderately-to-severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to 1 or more tumor necrosis factor (TNF) antagonists.
Limitations Of use:
Not recommended for use with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (eg, azathioprine, cyclosporine).
Take with or without food. 2mg once daily. May be used as monotherapy or in combination with methotrexate or other DMARDs. Dose modifications: see full labeling.
Serious infections. Malignancy. Thrombosis.
Increased risk of serious or fatal infections (eg, TB, bacterial, viral, invasive fungal, or other opportunistic pathogens). Avoid in active, serious, or localized infections. Chronic, recurrent, or history of serious or opportunistic infections. Travel to, or residence in, areas with endemic TB or mycoses. Conditions that predispose to infection. Test/treat latent TB infection prior to and per applicable guidelines during therapy. Monitor closely if new infection, active TB (even if initial latent test is negative), reactivation of herpes virus or hepatitis occurs; interrupt treatment if serious or opportunistic infection, or sepsis develops. Known malignancy. GI perforations risk (eg, history of diverticulitis). Thrombosis risk. Perform periodic skin exam in those with skin cancer risk. Update immunization based on current guidelines prior to initiating therapy. Do not initiate therapy if lymphocytes <500 cells/mm3, ANC <1000 cells/mm3, or hemoglobin <8g/dL. Monitor lymphocytes, neutrophils, and hemoglobin at baseline, then periodically thereafter. Routinely monitor liver enzymes; interrupt therapy if ALT/AST elevated and drug-induced liver injury is suspected. Monitor lipids 12 weeks following initiation. Renal impairment (eGFR <60mL/min/1.73m2) or severe hepatic impairment: not recommended. Elderly: monitor renal function. Pregnancy. Nursing mothers: not recommended.
Janus kinase (JAK) inhibitor.
Concomitant live vaccines, strong OAT3 inhibitors (eg, probenecid): not recommended.
Upper respiratory tract infections, nausea, herpes simplex, herpes zoster; other serious or opportunistic infections, TB, malignancies (eg, lymphoma), cytopenias, liver enzyme or lipid elevations, non-melanoma skin cancer, thrombosis.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Improving the Care of Aging Adults Living With HIV
- Infection Prevention Differs Between Small, Large Hospitals
- International Antiviral Society-USA Updates Recommendations for HIV Treatment and Prevention
- Previous Missed Appointments Predict Likelihood of Trend in Patients With HIV
- FDA Warns Against Long-Term Azithromycin Use for Some
- Identifying the Source of C difficile in Hospitalized Patients
- Antibiotics Often Unnecessary for Sacral Pressure Ulcers Complicated by Osteomyelitis
- Sensitivity and Specificity of 7 Treponemal Tests for Syphilis Diagnosis
- Automated EHR Algorithm More Effective Than Nurse-Driven Protocol for HCV, HIV Screening
- A Pan-Tuberculosis Regimen: The Debate Continues
- HCV Eradication in HIV/HCV-Coinfection Decreases Immune Activation
- Tolerability of Switching to Long-acting Cabotegravir Plus Rilpivirine From Current HIV-1 Regimen
- Time to Blood Culture Positivity Predictive of Mortality in S Aureus Infective Endocarditis
- C difficile Tied to Increased Graft Loss in Solid Organ Recipients
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd